Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.
Paulina J Haight, MD
Advertisement
Articles by Paulina J Haight, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5